Antimicrobial chemotherapy for legionnaires' disease: a review.
about
Characterization of members of the Legionellaceae family by automated ribotypingNosocomial pneumonia caused by three genetically different strains of Legionella pneumophila and detection of these strains in the hospital water supplyThe treatment of Legionnaires' disease.Comparative evaluation of three different genotyping methods for investigation of nosocomial outbreaks of Legionnaires' disease in hospitals.In vitro activities of gemifloxacin versus five quinolones and two macrolides against 271 Spanish isolates of Legionella pneumophila: influence of charcoal on susceptibility test results.Potential virulence role of the Legionella pneumophila ptsP orthologLegionnaires' disease and pneumonia. Beware the temptation to underestimate this "exotic" cause of infection.Current and emerging Legionella diagnostics for laboratory and outbreak investigations.Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumoniaOfloxacin versus standard therapy in treatment of community-acquired pneumonia requiring hospitalization. Pneumonia Study Group.Isolation of a gene encoding a novel spectinomycin phosphotransferase from Legionella pneumophilaLegionnaires' disease: update on epidemiology and management options.High-Throughput Intracellular Antimicrobial Susceptibility Testing of Legionella pneumophila.Current clinical management of Legionnaires' disease.The guinea pig as a model of infectious diseases.Coping with Legionella.In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia.In vitro activity of gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and its pharmacokinetics in guinea pigs with L. pneumophila pneumonia.In vitro activity of ABT-773 against Legionella pneumophila, its pharmacokinetics in guinea pigs, and its use to treat guinea pigs with L. pneumophila pneumonia.Simplified quantitative assay system for measuring activities of drugs against intracellular Legionella pneumophila.Susceptibilities of Legionella spp. to newer antimicrobials in vitro.Subinhibitory concentrations of antimicrobial agents reduce the uptake of Legionella pneumophila into Acanthamoeba castellanii and U937 cells by altering the expression of virulence-associated antigens.Antibacterial effects of levofloxacin, erythromycin, and rifampin in a human monocyte system against Legionella pneumophila.Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia.High Throughput, Real-time, Dual-readout Testing of Intracellular Antimicrobial Activity and Eukaryotic Cell Cytotoxicity.In vitro and intracellular activities of peptide deformylase inhibitor GSK1322322 against Legionella pneumophila isolatesTigecycline as a Second-Line Agent for Legionnaires' Disease in Severely Ill PatientsDetection of Legionella pneumophila on clinical samples and susceptibility assessment by flow cytometry.
P2860
Q30760461-1DC50DA1-9451-4445-8EE3-AE93B3C8F410Q33662256-D8FCA402-5095-47E7-9EF2-4D2AFCE3F952Q33686303-EEBF1DEA-121C-44FE-B86C-805CB519FEABQ33967468-A780A60C-308C-40C2-808E-D9D80C89E9A8Q33980280-C4909B71-4C66-400F-9BB6-52EC48387DE4Q34008479-CCFE4C52-4F1F-48BA-A35D-026DFC2DB748Q34267134-163E9820-5A3E-42EF-8562-A1AE440217EDQ34826656-9326982B-E0FD-4E23-8827-75C6D9968F48Q35122254-D4C924FA-13FB-4350-84B9-54A47D101BB5Q35124332-B98BAD4B-49B0-48EC-9C3A-EF0AEB9F57EAQ35136872-5508B48B-E373-4D79-BDB8-9F0F5722098BQ35627693-B7B4B924-681C-459C-BFB8-8366A984A0DEQ36290493-8098DB92-EA5E-4963-8BEA-126B35988374Q36688955-61F009FE-36EB-4D86-AC4A-D089A778271EQ37251175-D91875E4-8023-4552-AD70-439AB0EFB813Q39428816-7DE78C07-1027-459E-9E58-CB67A723E77BQ39469546-1111E571-17EE-4C0F-8D21-9338AC904494Q39477931-D20E71B0-5044-4086-8B2F-C43ACF1E5087Q39478420-472BA5B8-148E-4CC4-BD5E-8B2F54DAF2C7Q39553788-EDC2282C-0430-45FB-827E-BF82FECF23F4Q39557831-CB8860BD-8D6A-4D11-AE9E-D88DC0EE5C8AQ39559397-1B92AD8B-2976-43DE-B0B3-B57F22E48489Q39559639-BD70903A-076B-4DE1-A944-94A266B92224Q39740470-0F5FDA72-E7DB-480D-9554-1758EA03FA00Q40425452-8866C64F-4C51-4885-936F-B9C18CD38148Q41687404-39524CC4-8C18-479D-904E-E722CFD21405Q42270776-A565A9C9-359F-4CB3-BF21-7E4082804A10Q50492882-FDA8E435-DAD6-48DF-89A0-6AFABD411ADA
P2860
Antimicrobial chemotherapy for legionnaires' disease: a review.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh
1995年學術文章
@zh-hant
name
Antimicrobial chemotherapy for legionnaires' disease: a review.
@en
type
label
Antimicrobial chemotherapy for legionnaires' disease: a review.
@en
prefLabel
Antimicrobial chemotherapy for legionnaires' disease: a review.
@en
P1476
Antimicrobial chemotherapy for legionnaires' disease: a review
@en
P2093
Edelstein PH
P304
P356
10.1093/CLIND/21.SUPPLEMENT_3.S265
P407
P478
21 Suppl 3
P577
1995-12-01T00:00:00Z